Cat. No.: HY-N1429

Taurochenodeoxycholic acid sodium

(Synonyms: 12-Deoxycholyltaurine sodium)

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 6009-98-9
Formula: C₂₆H₄₄NNaO₆S
Molecular Weight:521.69

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Taurochenodeoxycholic acid sodium Chemical Structure

CAS No.: 6009-98-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]

Microbial Metabolite

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	1.92 μM Compound: 4a, tauro	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
HEK293	EC₅₀	2.3 μM Compound: TCDC	Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay	[PMID: 26435512]
HEK293	EC₅₀	29.57 μM Compound: TCDC	Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay	[PMID: 26435512]

In Vitro

Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid sodium significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Taurochenodeoxycholic acid (12-Deoxycholyltaurine; TCDCA; 0.05, 0.1g/kg) sodium decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2^[2].
Taurochenodeoxycholic acid sodium significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation^[3].
Taurochenodeoxycholic acid sodium significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 6009-98-9
Appearance Solid
Molecular Weight 521.69
Formula C₂₆H₄₄NNaO₆S
Color Off-white to light yellow
SMILES

C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
Synonyms

12-Deoxycholyltaurine sodium
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (12)

All Bio/Physico-chemical AssayHistological Imaging/StainingRT-PCR

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Nat Microbiol

Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen. [Abstract]

2023 Jan;8(1):91-106. PMID: 36604506
Nat Commun

The bacteroidal metabolite O-LysoPE facilitates hepatocyte-mediated immunosuppression in autoimmune hepatitis. [Abstract]

2026 Jun 16. PMID: 42304006
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Taurochenodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Cancer Lett

Bile acid retention impairs tumoral antigen presentation and intrinsic tumor suppression in MASH-HCC. [Abstract]

2026 Aug 28:654:218589. PMID: 42173274
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318

Taurochenodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]

Univariate analysis of major serum bile acids in WT d and e mice of control and SAP model. (3 mM TCDCA).

Taurochenodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]

A notable reduction in serum amylase and lipase levels was observed following TCDCA supplementation.

Taurochenodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]

TCDCA alleviates pancreatitis via TGR5 and NLRP3 signaling. 3 mM TCDCA was added to the drinking water for 4 weeks before caerulein injection SAP models. Samples were at 12 h post caerulein-induced SAP modeling (n=6).
Food Sci Hum Wellness

2026 Apr 6.
Cancer Cell Int

Taurochenodeoxycholic acid suppresses the progression of glioblastoma via HMGCS1/HMGCR/GPX4 signaling pathway in vitro and in vivo. [Abstract]

2025 Apr 22;25(1):160. PMID: 40264142
Food Funct

Association between daidzein metabolism to equol and fecal bile acid profiles in young women. [Abstract]

2026 Jun 22. PMID: 42329218
Biomedicines

The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia. [Abstract]

2025 Apr 4;13(4):874. PMID: 40299495
J Pharm Biomed Anal

Integrating 16S rDNA sequencing analysis and targeted metabolomics to explore the mechanism of Xiexin Tang in treating atherosclerosis mice induced by high-fat diet. [Abstract]

2025 Jul 15:259:116760. PMID: 40014894
SSRN

2022 Jan 26.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (191.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9168 mL

9.5842 mL

19.1685 mL

5 mM

0.3834 mL

1.9168 mL

3.8337 mL

10 mM

0.1917 mL

0.9584 mL

1.9168 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15. [Content Brief]

[2]. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5. [Content Brief]

[3]. Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57. [Content Brief]

[4]. Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9168 mL	9.5842 mL	19.1685 mL	47.9212 mL
	5 mM	0.3834 mL	1.9168 mL	3.8337 mL	9.5842 mL
	10 mM	0.1917 mL	0.9584 mL	1.9168 mL	4.7921 mL
	15 mM	0.1278 mL	0.6389 mL	1.2779 mL	3.1947 mL
	20 mM	0.0958 mL	0.4792 mL	0.9584 mL	2.3961 mL
	25 mM	0.0767 mL	0.3834 mL	0.7667 mL	1.9168 mL
	30 mM	0.0639 mL	0.3195 mL	0.6389 mL	1.5974 mL
	40 mM	0.0479 mL	0.2396 mL	0.4792 mL	1.1980 mL
	50 mM	0.0383 mL	0.1917 mL	0.3834 mL	0.9584 mL
	60 mM	0.0319 mL	0.1597 mL	0.3195 mL	0.7987 mL
	80 mM	0.0240 mL	0.1198 mL	0.2396 mL	0.5990 mL
	100 mM	0.0192 mL	0.0958 mL	0.1917 mL	0.4792 mL

Taurochenodeoxycholic acid sodium

12 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Taurochenodeoxycholic acid sodium

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Food-Sourced Compound Library

Human Metabolite Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

Cell Death Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Bile Acids Library

Publications Citing Use of MedChemExpress (MCE) Taurochenodeoxycholic acid sodium

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (12)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Taurochenodeoxycholic acid sodium Related Classifications

HY-N1429 Related Classifications